|Place of Origin:||CHINA|
|Model Number:||Antineoplastic Drugs API - 65|
|Minimum Order Quantity:||1KG|
|Packaging Details:||Aluminum foil bag, fiber can, kraft paper bag|
|Delivery Time:||Within 7 days|
|Supply Ability:||Can be customized according to customer requirements|
chemical raw materials,
pharmaceutical raw materials
Bms 582664 CAS 649735-63-7 Pharmaceutical Grade Chemicals
BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Hepatocellular carcinoma is a primary cancer of the liver and is more common in men than in women. The disease occurs mostly in people who have scarring of the liver (cirrhosis) or after infection with hepatitis B or hepatitis C. Symptoms include pain and swelling in the abdomen, weight loss, weakness, loss of appetite and nausea. Hepatocellular carcinoma is a severe and life-threatening disease that is associated with poor overall survival. While the choice of treatment depends mainly on how advanced the disease is, the only proven therapies to cure the cancer is surgery to remove the tumor and liver transplantation, but these therapies can only be carried out in very few patients. Other treatments include chemotherapy andimmunotherapy.
In clinical trials, brivanib was generally well tolerated. The most common adverse events included fatigue, hypertension, and diarrhea.
We can customize according to customer's requirement.
If you have any question pls mail us or call us.